Arcturus Therapeutics (NASDAQ:ARCT) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a strong sell rating to a sell rating in a research report report published on Sunday morning.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT opened at $7.41 on Friday. The business’s 50 day moving average price is $6.77 and its 200-day moving average price is $7.39. The firm has a market capitalization of $210.61 million, a PE ratio of -2.24 and a beta of 2.39. Arcturus Therapeutics has a 1 year low of $5.50 and a 1 year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.The firm had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $3.11 million. As a group, analysts expect that Arcturus Therapeutics will post -3.99 earnings per share for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $128,000. Millennium Management LLC purchased a new position in Arcturus Therapeutics in the first quarter worth approximately $4,892,000. Goldman Sachs Group Inc. increased its stake in Arcturus Therapeutics by 9.1% during the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock worth $5,398,000 after acquiring an additional 42,636 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Arcturus Therapeutics during the first quarter worth $701,000. Finally, Strs Ohio purchased a new stake in Arcturus Therapeutics in the first quarter valued at $89,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.